Leading investments into growth-stage technology and healthcare companies, William Staveacre brings operating and board experience to capital allocation decisions. He evaluates revenue model durability, unit economics, and founder-market fit to prioritize deals that can scale to exit via trade sale or IPO. Active in LP fundraising and syndicate formation, he contributes to portfolio governance and go-to-market execution. Prior roles encompass operating management and investment leadership, providing cross-functional insight into product, sales and financial operations.
Leading investments into growth-stage technology and healthcare companies, William Staveacre brings operating and board experience to capital allocation decisions. He evaluates revenue model durability, unit economics, and founder-market fit to prioritize deals that can scale to exit via trade sale or IPO. Active in LP fundraising and syndicate formation, he contributes to portfolio governance and go-to-market execution. Prior roles encompass operating management and investment leadership, providing cross-functional insight into product, sales and financial operations.
Focuses on growth-stage technology and healthcare companies, prioritizing repeatable revenue models, strong unit economics and clear founder-market fit. Allocates capital with a staged, milestone-driven approach that balances runway extension and go-to-market scaling, targeting exits via trade sale or IPO over a 3–7 year horizon. Employs active board engagement and operating partnership to de-risk commercial execution, leaning toward B2B SaaS, digital health and platform-enabled services. Investment decisions emphasize differentiated product defensibility, measurable growth efficiency and founder alignment; downside risk is managed through conviction-weighted positions and syndicate co-investment.
Focuses on growth-stage technology and healthcare companies, prioritizing repeatable revenue models, strong unit economics and clear founder-market fit. Allocates capital with a staged, milestone-driven approach that balances runway extension and go-to-market scaling, targeting exits via trade sale or IPO over a 3–7 year horizon. Employs active board engagement and operating partnership to de-risk commercial execution, leaning toward B2B SaaS, digital health and platform-enabled services. Investment decisions emphasize differentiated product defensibility, measurable growth efficiency and founder alignment; downside risk is managed through conviction-weighted positions and syndicate co-investment.
| Trades 7995 | Longs Won 3629/7995 45% | Profit Factor 1.16 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $281,069.03 |
| Average Win $48,688.4 | Best Trade (Oct 15) $8.34M | Sharpe Ratio -10.46 |
| Average Loss -$34,965.69 | Worst Trade (Oct 15) -$18.79M | Z-Score -4.45 (100%) |
| Commissions $0 | Avg. Trade Length 4m 2w 6d | Expectancy $3,012.62 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% | 1.11% |
| Consecutive Losing Trades | 15,152 | 13,636 | 12,121 | 10,606 | 9,091 | 7,576 | 6,061 | 4,545 | 3,030 | 1,515 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 8787 87877F103 | 81 | $6,266 | $6,266 | - | - | - | 0.0 |
A Agilent Technologies Inc. | 3,218 | $422,617.72 | $564,533.74 | - | $141,916.02 | 33.58% | +0.822% |
ABCB Ameris Bancorp | 151 | $13,629.26 | $11,963.73 | - | -$1,665.53 | -12.22% | +1.447% |
ACEL Accel Entertainment Inc. | 113 | $1,232.83 | $1,268.42 | - | $35.59 | 2.89% | +0.854% |
ACHV Achieve Life Sciences Inc. | 60,514 | $395,156.42 | $424,808.28 | - | $29,651.86 | 7.5% | +0.286% |
ACI Albertsons Companies, Inc. | 8,285 | $112,096.05 | $108,657.77 | - | -$3,438.28 | -3.07% | +0.268% |
ACVA ACV Auctions Inc. | 834 | $3,536.16 | $8,757 | - | $5,220.84 | 147.64% | 0.0 |
ADBE Adobe Inc. | 1,871 | $542,654.44 | $466,066.1 | - | -$76,588.34 | -14.11% | +3.498% |
ADI Analog Devices, Inc. | 3,046 | $986,045.89 | $1.22M | - | $232,384.57 | 23.57% | -0.882% |
ADMA Adma Biologics Inc. | 266 | $2,396.66 | $2,863.49 | - | $466.83 | 19.48% | +4.11% |
ADNT Adient plc | 222 | $4,080.36 | $3,991.56 | - | -$88.8 | -2.18% | +2.334% |
ADSK Autodesk, Inc. | 2,750 | $535,599.58 | $666,008.75 | - | $130,409.17 | 24.35% | +4.778% |
ADT ADT Inc. | 9,379 | $61,526.24 | $63,824.09 | - | $2,297.85 | 3.73% | +3.106% |
AEE Ameren Corporation | 212 | $23,964.48 | $22,062.84 | - | -$1,901.64 | -7.94% | -0.488% |
AESI Atlas Energy Solutions Inc. | 9,453 | $157,724.71 | $97,649.49 | - | -$60,075.22 | -38.09% | -6.685% |
AFL Aflac Inc. | 43,670 | $5.12M | $5.17M | - | $49,856.93 | 0.97% | +0.085% |
AGEN Agenus Inc. | 27,669 | $87,157.35 | $190,501.06 | - | $103,343.71 | 118.57% | +5.923% |
AGM Federal Agricultural Mortgage Corporation | 20 | $3,886 | $4,102 | - | $216 | 5.56% | +0.628% |
AGO Assured Guaranty Ltd. | 1,968 | $157,754.88 | $138,389.76 | - | -$19,365.12 | -12.28% | +1.943% |
AGYS Agilysys Inc. | 256 | $26,470.4 | $28,687.36 | - | $2,216.96 | 8.38% | +4.329% |